Penny stock trading can offer investors an exciting opportunity to potentially reap significant gains. While a lot of investors might concentrate on more well-known stocks listed on significant exchanges, there are a ton of low-priced stocks that are currently trading that may offer promising investment potential.
In this article, we'll be delving into the world of penny stock trading and examining four stocks that are currently trading at attractive prices. These stocks could have the potential to experience explosive growth, and we'll be taking a closer look at what these companies offer.
While investing in penny stocks can come with increased risk, it also presents the opportunity for big rewards. As investors, it's important to carefully analyze the potential of each stock and assess their long-term prospects.
Penny stocks offer an exciting opportunity to invest in promising companies at a low price. Let's explore what these four stocks have to offer and why they may be worth considering for your portfolio.
Epazz Inc. (OTCMKTS: EPAZ) is a mission-critical provider of drone technology, blockchain mobile apps, and cloud-based business software solutions. On March 7, Epazz announced that the company received the official utility patent on their AI-predictive drone Smart Charging Pad.
This now allows EPAZ to seek international patents using established U.S. patent treaties. They will concentrate on patent registration in Ukraine, the United Kingdom, the European Union, Canada, Australia, South Africa, and Brazil.
EPAZ believes that the Smart Charging Pad is a major game changer in the drone charging arena. While most competitors are pricing their charging pads for drones weighing less than 55 pounds anywhere from $4,000 to $15,000, the ZenaDrone Smart Charging Pad, which can be used to charge our ZenaDrone 1000, weighing over 250 pounds, will be priced at less than $15,000.
The ZenaDrone Smart Charging Pad allows the ZenaDrone 1000 to land on the charger for automatic charging. This allows the drone to be used in remote areas and operate in a true autonomous fashion. According to the company, the Smart Charging Pad has built-in computer vision to help it understand the environment around it and select the best option for receiving energy. It also has options for solar panels or wind power.
The ZenaDrone 1000, with its updated artificial intelligence (AI) predictive automation software, is a serious aircraft created for use by the military as well as in the oil and gas and agriculture industries. The ZenaDrone is meant to be a workhorse and to push the limits of future technology available today. The company's affordable offerings are getting noticed quickly.
Just a few weeks ago, back in February, EPAZ submitted Phase 1 SBIR proposals to the U.S. government. If ZenaDrone is awarded a Phase 1 contract, which has a value of up to $75,000 per proposal, the company will then be able to submit for Phase 2 contracts, which have a value of up to $1.2 million per contract. ZenaDrone will hear back from the government in 90 days.
Additional phases of the SBIR would give the business the opportunity to secure significant government contracts worth up to $15 million over the following three years. The company's prospects are also improved by the US government's ban on Chinese drones, which coincides with the significant revenue opportunity provided by SBIR contracts in the upcoming years. A further benefit of joining the program is that ZenaDrone will be permitted to sell its drones to US allies.
With the US Military drone segment set to expand, and the potential for big revenue over the next few years, EPAZ should be on the list of any investor looking for a promising penny stock
Houston Natural Resources Corp. (OTCMKTS: HNRC) is a diversified energy company with oil and gas interests as well as wastewater treatment facilities. The Halff Oil Field in Crockett County, Texas, has 83 oil wells with an estimated 33 million barrels of oil and water treatment and appraised reserves of $69 million. HNRC has acquired a 9.9% interest in Cunningham Energy LLC, which has an appraised reserve of $352 million.
On Tuesday, HNRC announced record results for the quarter ending in December 2022. HNRC increased revenue by 12.6% over 2021. Their total earnings increased by 24.9% over the previous year. Earnings per share for 2022 were $ 0.14 per share. HNRC has a net asset value of $ 1.35 per share as of December 31, 2022.
Frank Kristan, president of Houston Natural Resources Corp., commented, "The company's increase in revenues and earnings has been due to acquisitions and an increase in services it provides to its portfolio companies. The company sponsored a successful $86 million NYSE listing of an energy focused special purpose acquisition corporation in 2022 and acquired an interest in Cunningham Energy. We anticipate consistent growth from revenue and profit in 2023 in addition to other liquidity events for HNRC shareholders.
While the stock finished Tuesday up nearly 75%, ultimately it could not carry the momentum into Wednesday, and the stock fell 22.66%.
Keep it on your shortlist for potential breakouts.
Kiromic BioPharma Inc. (NASDAQ: KRBP) is a clinical-stage biotherapeutics company using its proprietary DIAMOND artificial intelligence 2.0 target discovery engine to detect, develop, and commercialize cell therapies with a therapeutic focus on immuno-oncology
Last week, the company celebrated a victory when they released promising news regarding a preclinical trial. According to KRBP, the company received favorable safety results from the histopathology evaluation of a preclinical study of the pharmacology of KB-GDT-01 (trademark: Deltacel) administered alone and in combination with a non-biological anti-tumor therapy in mice.
“These findings are in line with what we observed in a study evaluating Deltacel monotherapy at a dose more than 7 times higher than the maximum dose planned for the Deltacel clinical trial, and they confirm that Deltacel was well tolerated in mice, even when given as part of a combination therapy that further boosted its potency,” said Leonardo Mirandola, Ph.D., Chief Scientific Officer of Kiromic BioPharma.
Kiromic plans to submit the Deltacel IND application to the FDA in the current first quarter. If accepted, plans call for the activation of the clinical trial process to begin in the second quarter of 2023. The planned clinical study will evaluate Deltacel in combination with a non-biological anti-tumor therapy for the treatment of non-small cell lung cancer.'
The stock finished up 12.59% on Wednesday.
A big winner from Wednesday's after hours trading session is Neoleukin Therapeutics Inc. (NASDAQ: NLTX). This biopharmaceutical company uses "de novo" protein design technology to develop next-generation immunotherapies for cancer, inflammation, and autoimmunity.
Neoleukin employs sophisticated computational methods to create proteins with specific pharmaceutical properties that may provide a therapeutic advantage over native proteins.
NLTX announced earlier this week that it had hired SVB Securities to help it review strategic options for the business with the aim of increasing shareholder value. Neoleukin's Board of Directors approved a further corporate restructuring to conserve cash, which included a 70% reduction in the company's workforce, in connection with the evaluation of strategic alternatives. CEO Jonathan Drachman, M.D., will also be stepping down after a short transition. The company anticipates that this force reduction will be finished in the first half of 2023.
Razorpitch Inc. is a marketing communications and investor relations firm serving private, pre-IPO, and public companies. RazorPitch specializes in corporate, investor, and stakeholder communications. Our goal is to raise visibility, expand awareness, and increase value. To learn more, visit RazorPitch.com.
Disclaimers: The Private Securities Litigation Reform Act of 1995 provides investors a safe harbor in regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, assumptions, objectives, goals, assumptions of future events or performance are not statements of historical fact may be forward looking statements. Forward looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through use of words such as projects, foresee, expects, will, anticipates, estimates, believes, understands, or that by statements, indicating certain actions & quotes; may, could or might occur Understand there is no guarantee past performance is indicative of future results. Investing in micro-cap or growth securities is highly speculative and carries an extremely high degree of risk. It is possible that an investor's investment may be lost or due to the speculative nature of the companies profiled. RazorPitch is responsible for the production and distribution of this content. RazorPitch is not operated by a licensed broker, a dealer, or a registered investment advisor. It should be expressly understood that under no circumstances does any information published herein represent a recommendation to buy or sell a security.